Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
Ronald D. Feld, William Kenneth Evans, P. Coy et al. · Journal of Clinical Oncology · 1987
In order to assess the effect of scheduling of chemotherapy on the outcome of patients with limited small-cell lung cancer (SCLC), the Clinical Trials Group of the National Cancer Institute of Canada carried out a randomized trial comparing the alternation of cyclophosphamide, Adriamycin (Adria Laboratories, Columbus, OH; doxorubicin) and vincristine (CAV) with etoposide (VP-16) and cisplatin for six cycles to the administration of these two combinations in a sequential fashion (three cycles of CAV followed by three of VP-16/cisplatin). Three hundred eligible patients were enrolled on the trial from September 1981 to October 1984. All responding patients were also treated after completion of chemotherapy with thoracic irradiation in randomly allocated doses of 2,000 and 3,750 cGy. The complete response (CR) rate to chemotherapy was slightly, but not significantly, higher on the alternating arm (52% v 44%, P = .20). However, there was no difference in disease-free or overall survival on the alternating and sequential arms, respectively (47.3 weeks v 45.1 weeks, P = .26; 61.7 weeks v 59.5 weeks, P = .56). Data on the effect of radiotherapy dose on survival are not yet mature, but it does not appear the results of this portion of the trial will alter the interpretation of the chemotherapy comparison. Patient characteristics favorably influencing survival were female sex, good performance status, younger age, and absence of supraclavicular node involvement. Two interpretations of these and other results in SCLC are suggested: (1) the difference between the schedules used is too small for the predictions of the Goldie-Coldman model to be realized in a trial of this size, or (2) VP-16/cisplatin is actually a superior regimen and any schedule that exposes patients to these drugs early in treatment will produce improved results.
Cited by 141 works. doi:10.1200/jco.1987.5.9.1401
Authors
- Ronald D. Feld
- William Kenneth Evans
- P. Coy
- I. Hodson
- Alan S. MacDonald
- David Osoba
- David G. Payne
- W E Shelley
- Joseph L. Pater
References
- Rationale for the use of alternating non-cross-resistant chemotherapy.
- The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
- Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung
- Small cell lung cancer 1973–1983: Early progress and recent obstacles
- Small-Cell Carcinoma of the Lung: Combined Chemotherapy and Radiation
- Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
- cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.
- VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
- Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.
- Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.